Lakefront Biotherapeutics NV 1 News | NetDania.com

Lakefront Biotherapeutics NV

26.52

20-October-26 04:03:52

15 minutes delayed

Stocks

+0.04

+0.15%

Today's range

26.30 - 26.58

ISIN

BE0003818359

Source

Cboe

Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

14 Oct 2026 16:01:00 By Nasdaq GlobeNewswire
Acquisition of Own Shares

13 Oct 2026 16:01:00 By Nasdaq GlobeNewswire
Lakefront Receives Transparency Notification from Bank of America

08 Oct 2026 16:01:00 By Nasdaq GlobeNewswire
Acquisition of Own Shares

06 Oct 2026 16:01:00 By Nasdaq GlobeNewswire
Acquisition of Own Shares

29 Sep 2026 16:01:00 By Nasdaq GlobeNewswire
Acquisition of Own Shares

22 Sep 2026 16:01:00 By Nasdaq GlobeNewswire
Acquisition of Own Shares

15 Sep 2026 16:01:00 By Nasdaq GlobeNewswire
Acquisition of Own Shares

08 Sep 2026 16:02:00 By Nasdaq GlobeNewswire
Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

08 Sep 2026 16:01:00 By Nasdaq GlobeNewswire
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities

05 Jan 2026 16:01:00 By Nasdaq GlobeNewswire
Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus

18 Dec 2025 16:01:00 By Nasdaq GlobeNewswire
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025

08 Dec 2025 01:30:00 By Nasdaq GlobeNewswire
Galapagos Receives Transparency Notifications from Bank of America

26 Nov 2025 01:30:00 By Nasdaq GlobeNewswire
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update

05 Nov 2025 16:01:00 By Nasdaq GlobeNewswire
Galapagos to Present New Data from Cell Therapy Program at ASH 2025

03 Nov 2025 16:01:00 By Nasdaq GlobeNewswire
Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development

30 Oct 2025 16:01:00 By Nasdaq GlobeNewswire
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors

23 Oct 2025 16:01:00 By Nasdaq GlobeNewswire
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation

21 Oct 2025 01:30:00 By Nasdaq GlobeNewswire
Galapagos Announces Appointment of Fred Blakeslee as General Counsel

16 Oct 2025 16:01:00 By Nasdaq GlobeNewswire
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business

01 Oct 2025 16:01:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.